BerandaIMM • ASX
add
Immutep Ltd
Tutup sebelumnya
$0,24
Rentang hari
$0,23 - $0,24
Rentang tahun
$0,22 - $0,44
Kapitalisasi pasar
336,04Â jt AUD
Volume Rata-Rata
2,76Â jt
Rasio P/E
-
Hasil dividen
-
Bursa utama
ASX
Berita pasar
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (AUD) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 1,57Â jt | 49,13% |
Biaya operasional | 2,12Â jt | -11,84% |
Laba bersih | -11,19Â jt | -5,41% |
Margin laba bersih | -710,92 | 29,31% |
Penghasilan per saham | — | — |
EBITDA | -13,20Â jt | -18,90% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
| (AUD) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 159,26Â jt | 53,53% |
Total aset | 182,33Â jt | 47,29% |
Total liabilitas | 9,86Â jt | 21,00% |
Total ekuitas | 172,47 jt | — |
Saham yang beredar | 1,46 M | — |
Harga terhadap nilai buku | 1,96 | — |
Tingkat pengembalian aset | -18,11% | — |
Tingkat pengembalian modal | -18,96% | — |
Arus Kas
Perubahan kas bersih
| (AUD) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -11,19Â jt | -5,41% |
Kas dari operasi | -14,27Â jt | -54,72% |
Kas dari investasi | -31,41Â jt | -14.887,41% |
Kas dari pembiayaan | -213,58Â rb | 1,09% |
Perubahan kas bersih | -43,95Â jt | -346,60% |
Arus kas bebas | -8,37Â jt | -13,11% |
Tentang
Immutep Ltd is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech.
Prima currently has three main products in its pipeline, all acquired with Immutep:
Eftilagimod alpha, which is recombinant soluble LAG-3, used as an activator of antigen presenting cells. This product has completed a Phase IIa clinical study, where it doubled the expected response rate in HER2-negative metastatic breast cancer.
IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG-3+ activated T cells. This antibody has been licensed to GlaxoSmithKline.
IMP701, an antagonist monoclonal antibody to LAG3 for use in cancer. This product has been licensed to Novartis Wikipedia
CEO
Didirikan
2001
Situs
Karyawan
19
